Diagnostic Imaging, Disease and Radiopharmaceuticals

Targeted radiopharmaceuticals offer new hope for longer 'healthspans'

AuntMinnie

MARCH 15, 2024

However, increased longevity has brought on a troubling rise in chronic disease, diminishing the quality of life later in life. Centers for Disease Control and Prevention (CDC) found that more than a quarter of U.S. An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care.

Radiopharmaceuticals

Radiopharmaceuticals Radiation Disease Diagnostic Imaging

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Imaging Technology

DECEMBER 6, 2023

and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.

Diagnostic

Diagnostic Diagnostic Imaging Clinic Radiopharmaceuticals

Carolyn J. Anderson, PhD, Receives SNMMI 2024 Georg Charles de Hevesy Nuclear Pioneer Award

Imaging Technology

JUNE 10, 2024

The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto. More recently, she and her collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, recently approved for human studies by the FDA as an Investigational New Drug.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Disease Imaging

Illuminating the Future: Recent Breakthroughs in Nuclear Medicine Advancements (Maharashtra, Raigarh, Sangli, Satara, Sindhudurg, Solapur, Thane, Wardha, Washim, Yavatmal)

Future Teleradiology

NOVEMBER 27, 2023

Discuss how these advancements enhance imaging capabilities, providing clearer insights into physiological processes. Discuss how theranostic approaches integrate diagnostic imaging and targeted therapy for more personalized and effective treatments.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Imaging Modalities Radiation

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Health Science

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. POSLUMA was developed to assist physicians in the detection and localization of prostate cancer.

Diagnostic

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Health Science

GE HealthCare Introduces Groundbreaking Developments in Precision Care at SNMMI24

Imaging Technology

JUNE 20, 2024

More than half of the world’s population is underserved and lacks access to essential health services, and two-thirds have no access to diagnostic imaging. Product life extension & upgrades GE HealthCare is also proud to offer global refurbished medical equipment, helping to improve access to affordable, quality healthcare.

Healthcare

Healthcare Healthcare Nuclear Medicine Computed Tomography

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Imaging Technology

JULY 28, 2023

POSLUMA represents a new class of high-affinity PSMA-targeted PET radiopharmaceuticals based on novel radiohybrid technology and is labeled with the radioisotope 18F to provide readily available patient access and leverage the high image quality of 18F-labeled PSMA PET imaging to facilitate effective detection of disease.

Clinic

Clinic Diagnostic Radiopharmaceuticals Radiation

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

OCTOBER 5, 2023

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering.

Diagnose

Diagnose Diagnostic Disease Radiation

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

APRIL 3, 2023

produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 Blue Earth Diagnostics received U.S.

Clinic

Clinic Nuclear Medicine Radiopharmaceuticals Radiation

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Gauden , D.Phil., 18F-rhPSMA-7.3

Diagnostic

Diagnostic Radiopharmaceuticals Imaging Radiation

Breaking Ground: Exploring the Latest Innovations in the Field of Nuclear Medicine (Madhya Pradesh, Bhopal, Raisen, Rajgarh, Sehore, Vidisha, Morena, Sheopur, Bhind, Gwalior, Ashoknagar)

Future Teleradiology

NOVEMBER 21, 2023

Discuss how PET/CT and PET/MRI combinations offer superior imaging capabilities, providing both anatomical and functional information in a single examination. Advancements in Radiopharmaceuticals: Precision Imaging Agents: Discuss the latest developments in radiopharmaceuticals.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Teleradiology

Diagnostic Imaging Brief

Targeted radiopharmaceuticals offer new hope for longer 'healthspans'

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Trending Sources

Carolyn J. Anderson, PhD, Receives SNMMI 2024 Georg Charles de Hevesy Nuclear Pioneer Award

Illuminating the Future: Recent Breakthroughs in Nuclear Medicine Advancements (Maharashtra, Raigarh, Sangli, Satara, Sindhudurg, Solapur, Thane, Wardha, Washim, Yavatmal)

The rise of theranostics: Part 1 -- Gaining momentum

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

The rise of theranostics: Part 1 -- Gaining momentum

GE HealthCare Introduces Groundbreaking Developments in Precision Care at SNMMI24

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

The rise of theranostics: Part 3 -- What is a theranostics center?

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Breaking Ground: Exploring the Latest Innovations in the Field of Nuclear Medicine (Madhya Pradesh, Bhopal, Raisen, Rajgarh, Sehore, Vidisha, Morena, Sheopur, Bhind, Gwalior, Ashoknagar)

Stay Connected